What is HC Wainwright's Forecast for Invivyd Q1 Earnings?

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - HC Wainwright issued their Q1 2026 earnings estimates for Invivyd in a report issued on Wednesday, May 28th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.08 EPS and FY2028 earnings at $0.18 EPS.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Invivyd in a research note on Friday, May 16th.

Invivyd Stock Up 12.0%

Invivyd stock traded up $0.10 during mid-day trading on Thursday, hitting $0.95. The company had a trading volume of 3,013,670 shares, compared to its average volume of 4,499,263. The stock has a market cap of $113.93 million, a price-to-earnings ratio of -0.48 and a beta of 0.40. Invivyd has a 1 year low of $0.35 and a 1 year high of $2.74. The business has a fifty day moving average of $0.64 and a 200 day moving average of $0.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The company had revenue of $11.30 million for the quarter, compared to analysts' expectations of $34.45 million.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently modified their holdings of IVVD. Mithril II GP LP acquired a new stake in Invivyd in the fourth quarter valued at $4,981,000. AQR Capital Management LLC increased its position in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after buying an additional 391,617 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock valued at $135,000 after buying an additional 282,100 shares in the last quarter. Deutsche Bank AG increased its position in shares of Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after buying an additional 227,463 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after buying an additional 222,375 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.